September MIMS Update

We look at some of the recent changes to the medicines landscape, with new indications and contraindications  New Indications Dapagliflozin (propanediol monohydrate) (Forxiga) is now indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy. Dupilumab (Dupixent) is now indicated for

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Labelling problems revealed by study
Next World news wrapup: 7 September 2023